Girentuximab

Summary

Girentuximab (CHEMBL1743027) is a phase-3 clinical-stage antibody; indicated across 4 conditions including clear cell renal carcinoma and renal cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743027
Name	Girentuximab
Type	Antibody
Max phase	3

Also known as: CG-250, CG250, Girentuximab, Rencarex, WX-G250, GIRENTUXIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
clear cell renal carcinoma	3	MONDO:0005005	EFO:0000349
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
kidney cancer	3	MONDO:0002367	MONDO:0002367
urothelial carcinoma	1	MONDO:0040679	EFO:0008528

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00087022	PHASE3	COMPLETED	Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
NCT05663710	PHASE1/PHASE2	RECRUITING	Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).